Related Experiment Video
Updated: Jun 7, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
KP-1461: a novel anti-HIV drug in limbo?
Abstract:
The path of an experimental drug from the laboratory to U.S. Food and Drug Administration (FDA) approval is typically long, rocky, and uncertain. It is especially so for a drug that turns common wisdom on its head. Take KP-1461, a new type of antiretroviral drug from Koronis Pharmaceuticals in Seattle. Unlike all of the currently approved anti-HIV drugs, which aim to reduce the amount of virus in the body by blocking viral replication, KP-1461 was designed not to inhibit replication, but rather to force newly created HIV to become less able to infect human cells.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
07:18High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
Published on: January 22, 2019
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis